Quick Answer
Viking Therapeutics, Inc. reported R&D Expense of $344.95 million for fiscal year 2025.
Viking Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $344.95M | +239.4% |
| 2024 | $101.64M | +59.3% |
| 2023 | $63.81M | +17.6% |
| 2022 | $54.23M | +20.6% |
| 2021 | $44.98M | +40.9% |
| 2020 | $31.93M | +35.5% |
| 2019 | $23.56M | +23.7% |
| 2018 | $19.04M | +38.6% |
| 2017 | $13.74M | +52.7% |
| 2016 | $9.00M | +29.2% |
| 2015 | $6.97M | -68.7% |
| 2014 | $22.22M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $89.95M | +294.8% | +49.5% |
| June 30, 2025 | $60.15M | +153.1% | +45.3% |
| March 31, 2025 | $41.39M | +71.7% | +81.7% |
| September 30, 2024 | $22.79M | +24.0% | -4.1% |
| June 30, 2024 | $23.77M | +70.8% | -1.4% |
| March 31, 2024 | $24.10M | +119.0% | +31.1% |
| September 30, 2023 | $18.38M | +53.7% | +32.1% |
| June 30, 2023 | $13.92M | +2.8% | +26.4% |
- Viking Therapeutics, Inc. showed an increase of +239.4% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Viking Therapeutics, Inc.’s r&d expense has grown by 1452.2% (from $22.22 million to $344.95 million).
- The most recent figure is from Viking Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: